GLP-1 Drugs Linked to Reduced Risk of Obesity-Related Cancers in Large Meta-Analysis | Research

The takeaway

A systematic review and meta-analysis found GLP-1 RA use associated with reduced risk of multiple obesity-related cancers in patients with type 2 diabetes and/or obesity.

Reduced cancer risk
GLP-1 RA use associated with lower obesity-related cancer incidence in T2DM/obesity patients

What the researchers found

GLP-1 RA use was associated with reduced risk of obesity-related cancers in patients with type 2 diabetes and/or obesity across combined RCT and observational evidence.

Why it matters

If GLP-1 RAs reduce cancer risk, this would be an enormous additional benefit beyond their metabolic effects, potentially preventing thousands of cancers annually.

How the study worked

Systematic review and meta-analysis; Embase, PubMed, and CENTRAL searched through November 2025; included RCTs and observational studies of adults with T2DM and/or obesity.

What this study cannot tell us

Observational data subject to confounding; relatively short follow-up for cancer outcomes; weight loss itself may explain some cancer risk reduction.

How to read the evidence

Systematic review and meta-analysis combining RCTs and observational studies — strong synthesis but cancer was not a primary endpoint in most included studies.

When this study was published

Published 2026 in Diabetes Research and Clinical Practice. Searches through November 2025.

The bigger picture

Cancer risk reduction would further strengthen the case for GLP-1 RAs as transformative medicines — from diabetes drugs to multi-organ protective agents including cancer prevention.

Questions still open

Is the cancer risk reduction mediated by weight loss, direct GLP-1R effects, or both?
Will dedicated cancer prevention trials of GLP-1 RAs be conducted?

Common questions

Can GLP-1 drugs reduce cancer risk?

This meta-analysis found GLP-1 RA use was associated with lower risk of obesity-related cancers. While promising, more research is needed to confirm whether the drugs directly prevent cancer or if the benefit comes from weight loss.

Which cancers might be reduced?

The study examined obesity-related cancers, which include types like breast, colorectal, endometrial, kidney, and liver cancers that are more common in people with obesity and diabetes.

Read the original research

Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.

Diabetes research and clinical practice, 113158

View on PubMed ↗Publisher’s paper ↗

Citation

Ateiwi, Yousef A; Mahmood, Rahil; Wong, Hon Jen; Low, Chen Ee; Yau, Chun En; Yan Bin Lee, Ainsley Ryan; Eng, Pei Chia; Lee, Matilda; Chan, Mark Y; Sia, Ching-Hui. (2026). Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.. Diabetes research and clinical practice, 113158. https://doi.org/10.1016/j.diabres.2026.113158